Attorney Docket No. 5470-368 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Jenny Ting et al.
Application No.: 10/511,989
Filed: May 25, 2005
For: Caterpiller gene family

Confirmation No.: 4540
Group Art Unit: 1633
Examiner: Scott David Priebe

Date: December 20, 2005

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)

Sir:

Attached is a list of documents on Form PTO-1449, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the amendment by the U.S. Patent and Trademark Office to 37 C.F.R. § 1.98(a)(2)(ii) effective October 21, 2004.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b), within three months of the filing date of the above-referenced application or before the mailing of a first Office Action on the merits, whichever event occurs last. Therefore, no fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. §1.56 and Section 609 of the MPEP.

Respectfully submitted,

Karen A. Magri
Registration No. 41,965

Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428
Raleigh, North Carolina 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401
Customer No. 20792

Certificate of Mailing under 37 CFR § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on December 20, 2005.

Sheena L. Donnelly

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)	Attorney Docket Number 5470-368	Serial No. 10/511,989
	Applicants: Jenny Ting et al..	
	Filing Date: May 25, 2005	Group: 1633

U. S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1.	6,432,442	08-13-2002	Bertin, et al.	435	7.92	
	2.	2001/0029033	10-11-2001	Shami et al.	435	69.1	
	3.	2003/0027757	02-06-2003	Bertin et al.	514	12	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes | No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	4.	Accession Number AF389420, *Homo sapiens* NOD27 (NOD27) mRNA, complete cds; Source: *Homo sapiens* (June 4, 2001)
	5.	Accession No. AF231021; *Homo sapiens* Leucine-Rich-Repeat Protein RNO2 mRNA, complete cds; Source: *Homo sapiens*; (2001)
	6.	Accession No. NM_033297; *Homo sapiens* Neuronal Apoptosis Inhibitor Protein 12 (NALP12), mRNA; Source: *Homo sapiens* (2003)
	7.	Accession Number AF526389; *Homo sapiens* cryopyrin (CIAS1) gene, intron 6; Source: *Homo sapiens* (July 2, 2002)
	8.	Accession Number AK025131; *Homo sapiens* cDNA: FLJ21478 fis, clone COL05012; Source: *homo sapiens* (August 29, 2000)
	9.	Accession Number AK025212; *Homo sapiens* cDNA: FLJ21559 fis, clone COL06406; Source: *Homo sapiens*
	10.	Accession Number AK025362; *Homo sapiens* cDNA: FLJ21709 fis, clone COL10077; Source: *Homo sapiens* (August 29, 2000)
	11.	Accession Number AK027416; *Homo sapiens* cDNA FLJ14510 fis, clone NT2RM1000623, weakly similar to RIBONUCLEASE INHIBITOR; Source: *Homo sapiens* (May 10, 2001)
	12.	Accession Number AK074109; *Homo sapiens* mRNA for FLJ00180 protein; Source: *Homo sapiens* (January 21, 2002)
	13.	Accession Number AK074133; *Homo sapiens* mRNA for FLJ00206 protein, Source: *Homo sapiens* (January 21, 2002)
	14.	Accession Number AK074182; *Homo sapiens* mRNA for FLJ00255 protein, Source: *Homo sapiens* (January 21, 2002)

EXAMINER _____ DATE CONSIDERED

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)	Attorney Docket Number 5470-368	Serial No. 10/511,989
	Applicants: Jenny Ting et al..	
	Filing Date: May 25, 2005	Group: 1633

	15.	Accession Number AK090431; *Homo sapiens* mRNA for FLJ00348 protein; Source: *Homo sapiens* (July 4, 2002)
	16.	Accession Number AK090439; *Homo sapiens* mRNA for FLJ00359 protein; Source: *Homo sapiens* (July 4, 2002)
	17.	Accession Number AK090476; *Homo sapiens* mRNA for FLJ00398 protein; Source: *Homo sapiens* (July 4, 2002)
	18.	Accession Number AK097030; *Homo sapiens* cDNA FLJ39711 fis, clone SMINT2013032; Source: *Homo sapiens* (July 4, 2002)
	19.	Accession Number AY051112; *Homo sapiens* cryopyrin (CIAS1) gene, exon 1; Source: *Homo sapiens* (August 15, 2001)
	20.	Accession Number AY051113; *Homo sapiens* cryopyrin (CIAS1) gene, exon 2; Source: *Homo sapiens* (August 15, 2001)
	21.	Accession Number AY051114; *Homo sapiens* cryopyrin (CIAS1) gene, exon 3; Source: *Homo sapiens* (August 15, 2001)
	22.	Accession Number AY051115; *Homo sapiens* cryopyrin (CIAS1) gene, exon 5; Source: *Homo sapiens* (August 15, 2001)
	23.	Accession Number AY051116; *Homo sapiens* cryopyrin (CIAS1) gene, exons 7 and 8; Source: *Homo sapiens* (August 15, 2001)
	24.	Accession Number AY051117; *Homo sapiens* cryopyrin (CIAS1) gene, exon 9 and complete cds, alternatively spliced; Source: *Homo sapiens* (August 15, 2001)
	25.	Accession Number AY056059; *Homo sapiens* cryopyrin (CIAS1) gene, exon 4; Source: *Homo sapiens* (August 15, 2001)
	26.	Accession Number AY056060; *Homo sapiens* cryopyrin (CIAS1) gene, exon 6; Source: *Homo sapiens* (August 15, 2001)
	27.	Accession Number AY092033; *Homo sapiens* NALP3 intermediate isoform (NALP3) mRNA, complete cds; Source: *Homo sapiens* (March 27, 2002)
	28.	Accession Number AY116204; *Homo sapiens* monarch-1 mRNA, complete cds; alternatively spliced; Source: *Homo sapiens* (May 29, 2002)
	29.	Accession Number AY116205; Accession Number AY116207; Homo sapiens monarch-1 splice form II mRNA, complete cds; alternatively spliced; Source: *Homo Sapiens* (May 29, 2002)
	30.	Accession Number AY116206; *Homo sapiens* monarch-1 splice form III mRNA, complete cds; alternatively spliced; Source: *Homo Sapiens* (May 29, 2002)
	31.	Accession Number AY116207; Homo sapiens monarch-1 splice form IV mRNA, complete cds; alternatively spliced; Source: *Homo Sapiens* (May 29, 2002)
	32.	Accession Number AY154469; *Homo sapiens* NALP14 (NALP14) mRNA, complete cds; Source: *Homo sapiens* (September 25, 2002)
	33.	Accession Number BC013199; *Homo sapiens* NOD9 protein, mRNA (cDNA clone IMAGE: 4387619),

EXAMINER _____ DATE CONSIDERED

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)	Attorney Docket Number 5470-368	Serial No. 10/511,989
	Applicants: Jenny Ting et al..	
	Filing Date: May 25, 2005	Group: 1633

		partial cds; Source: *Homo sapiens* (August 27, 2001)
	34.	Accession Number NM_004895 *Homo sapiens* cold auto inflammatory syndrome 1 (CIAS1), transcript variant 1, mRNA; Source: *Homo sapiens* (2004)
	35.	Accession Number NM_024618; *Homo sapiens* NOD9 protein (NOD9), transcript variant 1, mRNA; Source: *Homo sapiens* (2003)
	36.	Accession Number NM_145827; *Mus musculus* cold auto inflammatory syndrome 1 homolog (human) (Cias1), mRNA; Source: *Mus musculus* (2003)
	37.	Accession Number NM_170722; *Homo sapiens* NOD9 protein (NOD9), transcript variant 2, mRNA; Source: *Homo sapiens* (2003)
	38.	Accession Number NT_009325; *Homo sapiens* chromosome 11 genomic contig; Source: *Homo sapiens* (2003)
	39.	Accession Number NT_009334; *Homo sapiens* chromosome 11 working draft sequence segment; Source: *Homo sapiens* (August 23, 2001)
	40.	Accession Number NT_015360; *Homo sapiens* chromosome 16 working draft sequence segment; Source: *Homo sapiens* (February 6, 2002)
	41.	Accession Number NT_024766; *Homo sapiens* chromosome 16 working draft sequence segment; Source: *Homo sapiens* (February 6, 2002)
	42.	Aganna, et al. 2002. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. *Arthritis Rheum* 46:2445.
	43.	Akira, et al. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. *Nat Immunol* 2:675.
	44.	Alexopoulou, et al. 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. *Nature* 413:732.
	45.	Banerjee, et al. 2001. The leucine-rich repeat domain can determine effective interaction between RPS2 and other host factors in arabidopsis RPS2-mediated disease resistance. *Genetics* 158:439.
	46.	Beg, et al. 1993. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. *Mol Cell Biol* 13:3301.
	47.	Bertin and DiStefano. 2000. The PYRIN domain: a novel motif found in apoptosis and inflammation proteins. *Cell Death Differ.* 7:1273.
	48.	Bertin, et al. 1999. Human CARD4 protein is a novel CED-4/Apaf-1 cell death family member that activates NF-kappaB. *J Biol Chem* 274:12955.
	49.	Beutler, B. 2001. Autoimmunity and apoptosis: the Crohn's connection. *Immunity* 15:5.
	50.	Bouchier-Hayes, et al. 2001. CARDINAL, a novel caspase recruitment domain protein, is an inhibitor of multiple NF-kappa B activation pathways. *J Biol Chem* 276:44069.
	51.	Brown, et al. 1998. The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element. *Nucleic.Acids.Res.* 26:4128.

EXAMINER _____ DATE CONSIDERED

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)	Attorney Docket Number 5470-368	Serial No. 10/511,989
	Applicants: Jenny Ting et al..	
	Filing Date: May 25, 2005	Group: 1633

	52.	Buchanan and Gay. 1996. Structural and functional diversity in the leucine-rich repeat family of proteins. *Prog Biophys Mol Biol.* 65:1.
	53.	Chen and Goeddel. 2002. TNF-R1 signaling: a beautiful pathway. *Science* 296:1634
	54.	Cressman, et al. 1999. A defect in the nuclear translocation of CIITA causes a form of type II bare lymphocyte syndrome. *Immunity.* 10:163.
	55.	Dangl and Jones. 2001. Plant pathogens and integrated defence responses to infection. *Nature* 411:826.
	56.	Dodds, et al. 2001. Six Amino Acid Changes Confined to the Leucine-Rich Repeat beta-Strand/beta-Turn Motif Determine the Difference between the P and P2 Rust Resistance Specificities in Flax. *Plant Cell* 13:163.
	57.	Dode, et al. 2002. New Mutations of CIAS1 That Are Responsible for Muckle-Wells Syndrome and Familial Cold Urticaria: A Novel Mutation Underlies Both Syndromes. *Am J Hum Genet* 70:1498.
	58.	Dowds, et al. 2003. Regulation of cryopyrin/Pypaf1 signaling by pyrin, the familial Mediterranean fever gene product. *Biochem. Biophys. Res. Commun.* 302(3):575-80.
	59.	Feldmann, et al. 2002. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. *Am J Hum Genet* 71:198.
	60.	Fiorentino, et al. 2002. A novel PAAD-containing protein that modulates NF-kappa B induction by cytokines tumor necrosis factor-alpha and interleukin-1beta. *J Biol Chem* 277:35333.
	61.	Fontes, et al. 1999. Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes. *Mol.Cell Biol.* 19:941.
	62.	Fukui et al. "Haematopoietic Cell-Specific CDM Family Protein DOCK2 is Essential for Lymphocyte Migration" *Nature* 412: 826-831 (2001)
	63.	Hake, et al. 2000. CIITA leucine-rich repeats control nuclear localization, In vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation [In Process Citation]. *Mol.Cell.Biol* 20(20):7716-25.
	64.	Harton and Ting. 2000. Class II transactivator: mastering the art of major histocompatibility complex expression. *Mol.Cell Biol* 20(17):6185-94.
	65.	Harton, et al. 1999. GTP binding by class II transactivator: role in nuclear import. *Science* 285:1402.
	66.	Harton, et al. 2002. Leucine-rich repeats of the class II transactivator control its rate of nuclear accumulation. *Hum Immunol.* 63(7):588-601
	67.	Heery, et al. 1997. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. *Nature* 387:733.
	68.	Hemmi, et al. 2000. A Toll-like receptor recognizes bacterial DNA. *Nature* 408:740.
	69.	Hlaing, et al. 2001. Molecular cloning and characterization of DEFCAP-L and -S, two isoforms of a novel member of the mammalian Ced-4 family of apoptosis proteins. *J.Biol.Chem.* 276(12):9230-8.
	70.	Hoffman, et al. 2001. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. *Nat. Genet.* 29:301.

EXAMINER _____ DATE CONSIDERED

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)	Attorney Docket Number 5470-368	Serial No. 10/511,989
	Applicants: Jenny Ting et al..	
	Filing Date: May 25, 2005	Group: 1633

	71.	Holt, et al. 2003. Resistance gene signaling in plants - complex similarities to animal innate immunity. *Curr Opin Immunol* 15:20.
	72.	Hugot, et al. 2001. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature* 411:599.
	73.	Inohara, et al. 1999. Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor- kappaB. *Journal of Biological Chemistry* 274:14560.
	74.	Inohara, et al. 2000. An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways. *J Biol Chem* 275:27823.
	75.	Inohara, et al. 2001. Human nod1 confers responsiveness to bacterial lipopolysaccharides. *J.Biol.Chem.* 276(4):2551-4.
	76.	International Search Report for International Patent Application No. PCT/US03/13562 mailed on October 1, 2004
	77.	Kaisho and Akira. 2000. Critical roles of Toll-like receptors in host defense. *Crit Rev Immunol* 20:393.
	78.	Koonin and Aravind. 2000. The NACHT family - a new group of predicted NTPases implicated in apoptosis and MHC transcription activation. *Trends.Biochem.Sci.* 25(5):223-4.
	79.	Kretsovali, et al. 1998. Involvement of CREB binding protein in expression of major histocompatibility complex class II genes via interaction with the class II transactivator. *Mol.Cell Biol.* 18:6777.
	80.	Kretsovali, et al. 2001. Self-association of CIITA correlates with its intracellular localization and transactivaiton. *J.Biol.Chem.* 276(34):32191-7.
	81.	Li and Verma. 2002. NF-kappaB regulation in the immune system. *Nat Rev Immunol* 2:725.
	82.	Linhoff, et al. 2001. Two distinct domains within CIITA mediate self-association: involvement of the GTP-binding and leucine-rich repeat domains. *Mol.Cell Biol* 21(9):3001-11.
	83.	MacKeigan, et al. 2000. MEK inhibition enhances paclitaxel-induced tumor apoptosis. *J Biol Chem* 275:38953.
	84.	Manji, et al. 2002. PYPAF1, a PYRIN-containing Apaf1-like protein that assembles with ASC and regulates activation of NF-kappa B. *J Biol Chem* 277:11570.
	85.	Martinon, et al. 2002. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. *Mol Cell* 10:417.
	86.	Masternak, et al. 2000. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. *Genes and Development* 14:1156.
	87.	Miceli-Richard, et al. 2001. CARD15 mutations in Blau syndrome. *Nat Genet* 29:19.
	88.	Nelson, L. M. 2001. Autoimmune ovarian failure: comparing the mouse model and the human disease. *J Soc Gynecol Investig* 8:S55.
	89.	Nickerson, et al. 2001. Dendritic cell-specific MHC class II transactivator contains a caspase recruitment domain that confers potent transactivation activity. *J Biol Chem* 276:19089.
	90.	Ogura, et al. 2001. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. *Nature* 411(6837):603-606.

EXAMINER _____ DATE CONSIDERED

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)	Attorney Docket Number 5470-368	Serial No. 10/511,989
	Applicants: Jenny Ting et al..	
	Filing Date: May 25, 2005	Group: 1633

	91.	Ogura, et al. 2001. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. *J Biol Chem* 276:4812.
	92.	Pan, et al. 2000. Divergent evolution of plant NBS-LRR resistance gene homologues in dicot and cereal genomes. *J Mol Evol* 50:203.
	93.	Phillips et al. "Expression of RNO-2 Inhibits Growth and Induces Differentiation and Apoptosis in leukemia Cells" *Blood* 98(11): 192b (2001) (Abstract)
	93.	Poltorak, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. *Science* 282:208.
	95.	Reith and Mach. 2001. The bare lymphocyte syndrome and the regulation of MHC expression. *Annu Rev Immunol* 19:331
	96.	Riley, et al. 1995. Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA). *Immunity* 2:533.
	97.	Samuels, et al. 1998. Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. *Medicine (Baltimore)* 77:268.
	98.	Schuster and Nelson. 2000. Toll receptors: an expanding role in our understanding of human disease. *J.Leukoc.Biol.* 67(6):767-73.
	99.	Schwandner, et al. 1999. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. *J Biol Chem* 274:17406.
	100.	Shami et al. "Identification and Characterization of a Novel Gene that is Upregulated in Leukaemia Cells by Nitric Oxide" *British Journal of Haematology* 112(1): 138-147 (2001)
	104.	Shami, et al. 2001. Identification and characterization of a novel gene that is upregulated in leukaemia cells by nitric oxide. *Br J Haematol* 112:138
	102.	Sisk, et al. 2000. MHC class II transactivator inhibits IL-4 gene transcription by competing with NF-AT to bind the coactivator CREB binding protein (CBP)/p300. *J.Immunol.* 165(5):2511-7.
	103.	Sisk, et al. 2001. Self-association of CIITA and its transactivation potential. *Mol Cell Biol* 21:4919.
	104.	Spilianakis, et al. 2000. Acetylation by PCAF enhances CIITA nuclear accumulation and transactivation of major histocompatibility complex class II genes. *Mol.Cell.Biol.* 20(22):8489-98.
	105.	Srinivasula et al. "The PYRIN-CARD Protein ASC is an Activating Adaptor for Capase-1" *The Journal of Biological Chemistry* 277(24): 21119-21122 (2002)
	106.	Stehlik, et al. 2002. The PAAD/PYRIN-family protein ASC is a dual regulator of a conserved step in nuclear factor kappaB activation pathways. *J Exp Med* 196:1605.
	107.	Steimle, et al. 1993. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). *Cell* 75:135.
	108.	Suzuki, et al. 2002. IRAK-4 as the central TIR signaling mediator in innate immunity. *Trends Immunol* 23:50.
	109.	Tong, et al. 2000. Mater encodes a maternal protein in mice with a leucine-rich repeat domain homologous to porcine ribonuclease inhibitor. *Mamm Genome* 11:281.

EXAMINER _____ DATE CONSIDERED

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)	Attorney Docket Number 5470-368	Serial No. 10/511,989
	Applicants: Jenny Ting et al..	
	Filing Date: May 25, 2005	Group: 1633

	107.	Steimle, et al. 1993. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). *Cell* 75:135.
	108.	Suzuki, et al. 2002. IRAK-4 as the central TIR signaling mediator in innate immunity. *Trends Immunol* 23:50.
	109.	Tong, et al. 2000. Mater encodes a maternal protein in mice with a leucine-rich repeat domain homologous to porcine ribonuclease inhibitor. *Mamm Genome* 11:281.
	110.	Tong, et al. 2000. Mater, a maternal effect gene required for early embryonic development in mice. *Nat Genet* 26:267.
	111.	Torchia, et al. 1997. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. *Nature* 387:677.
	112.	Towey and Kelly. 2002. Nuclear localisation of CIITA is controlled by a carboxy terminal leucine-rich repeat region. *Mol Immunol* 38:627.
	113.	Traut, T. W. 1994. The functions and consensus motifs of nine types of peptide segments that form different types of nucleotide-binding sites. *Eur J Biochem* 222:9.
	114.	Tschopp et al. "NALPS: A Novel Protein Family Involved in Inflammation" *Nature Reviews* 4(2): 95-104 (2003)
	115.	Van Der Hoorn, et al. 2001. Identification of distinct specificity determinants in resistance protein cf-4 allows construction of a cf-9 mutant that confers recognition of avirulence protein avr4. *Plant Cell* 13:273.
	116.	Wang, et al. 2002. PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-kappa B and caspase-1-dependent cytokine processing. *J. Biol. Chem.* 277(33):29874-80
	117.	Williams et al. "Cutting Edge: Monarch-1: A Pyrin/Nucleotide-Binding Domain/Leucine-Rich Repeat Protein that Controls Classical and nonclassical MHC Class I Genes" *The Journal of Immunology* 170: 5354-5358 (2003)
	118.	Wong, et al. 2002. Regulation and specificity of MHC2TA promoter usage in human primary T lymphocytes and cell line. *J Immunol* 169:3112.
	119.	Yao and Cooper. 1995. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. *Science* 267:2003.
	120.	Zhang, et al. 1999. Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. *J Biol Chem* 274:7611.
	121.	Zhou and Glimcher. 1995. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency. *Immunity*. 2:545.
	122.	Zhu, et al. 2000. Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter. *Mol.Cell Biol* 20(16):6051-61.

EXAMINER _____ DATE CONSIDERED

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.